Literature DB >> 16325781

Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.

Erik G Lund1, Laurence B Peterson, Alan D Adams, My-Hanh N Lam, Charlotte A Burton, Jayne Chin, Qiu Guo, Shaei Huang, Melanie Latham, Jacqueline C Lopez, John G Menke, Denise P Milot, Lyndon J Mitnaul, Sandra E Rex-Rabe, Raymond L Rosa, Jenny Y Tian, Samuel D Wright, Carl P Sparrow.   

Abstract

Liver X receptor (LXR) alpha and LXRbeta are closely related nuclear receptors that respond to elevated levels of intracellular cholesterol by enhancing transcription of genes that control cholesterol efflux and fatty acid biosynthesis. The consequences of inactivation of either LXR isoform have been thoroughly studied, as have the effects of simultaneous activation of both LXRalpha and LXRbeta by synthetic compounds. We here describe the effects of selective activation of LXRalpha or LXRbeta on lipid metabolism. This was accomplished by treating mice genetically deficient in either LXRalpha or LXRbeta with an agonist with equal potency for both isoforms (Compound B) or a synthetic agonist selective for LXRalpha (Compound A). We also determined the effect of these agonists on gene expression and cholesterol efflux in peritoneal macrophages derived from wild-type and knockout mice. Both compounds raised HDL-cholesterol and increased liver triglycerides in wild-type mice; in contrast, in mice deficient in LXRalpha, Compound B increased HDL-cholesterol but did not cause hepatic steatosis. Compound B induced ATP-binding cassette transporter (ABC) A1 expression and stimulated cholesterol efflux in macrophages from both LXRalpha and LXRbeta-deficient mice. Our data lend further experimental support to the hypothesis that LXRbeta-selective agonists may raise HDL-cholesterol and stimulate macrophage cholesterol efflux without causing liver triglyceride accumulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325781     DOI: 10.1016/j.bcp.2005.11.004

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  43 in total

Review 1.  Liver X receptors as integrators of metabolic and inflammatory signaling.

Authors:  Noam Zelcer; Peter Tontonoz
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 2.  Liver X receptors as therapeutic targets in metabolism and atherosclerosis.

Authors:  Takashi Nomiyama; Dennis Bruemmer
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

Review 3.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

4.  Molecular mechanisms underlying the fetal programming of adult disease.

Authors:  Thin Vo; Daniel B Hardy
Journal:  J Cell Commun Signal       Date:  2012-05-24       Impact factor: 5.782

5.  LXRα gene expression, genetic variation and association analysis between novel SNPs and growth traits in Chinese native cattle.

Authors:  Yun Ma; Ningbo Chen; Rongrong Li; Yongjie Xu; Fen Li; Junya Li; Shuxin Gao; Xiaofeng Li; Kuilin Shi
Journal:  J Appl Genet       Date:  2013-10-10       Impact factor: 3.240

6.  NURR1 activation in skeletal muscle controls systemic energy homeostasis.

Authors:  Leonela Amoasii; Efrain Sanchez-Ortiz; Teppei Fujikawa; Joel K Elmquist; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-20       Impact factor: 11.205

7.  Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.

Authors:  Eric D Bischoff; Chris L Daige; Mary Petrowski; Harry Dedman; Jennifer Pattison; Joseph Juliano; Andrew C Li; Ira G Schulman
Journal:  J Lipid Res       Date:  2010-05       Impact factor: 5.922

8.  Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.

Authors:  Cristiano P Vieira; Seth D Fortmann; Masroor Hossain; Ana Leda Longhini; Sandra S Hammer; Bright Asare-Bediako; David K Crossman; Micheli S Sielski; Yvonne Adu-Agyeiwaah; Mariana Dupont; Jason L Floyd; Sergio Li Calzi; Todd Lydic; Robert S Welner; Gary J Blanchard; Julia V Busik; Maria B Grant
Journal:  JCI Insight       Date:  2020-07-09

Review 9.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

Review 10.  Flavonoids as dietary regulators of nuclear receptor activity.

Authors:  Yishai Avior; David Bomze; Ory Ramon; Yaakov Nahmias
Journal:  Food Funct       Date:  2013-04-19       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.